Severe Pneumonia In Children (S-PIC) Study: A Comparative Effectiveness Study Of Children With Severe Pneumonia In Asia

Pneumonia Clinical Trial

Official title:

Severe Pneumonia In Children (S-PIC) Study: A Comparative Effectiveness Study Of Children With Severe Pneumonia In Asia

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04265287
• Other study ID #: S-PIC
• Status: Completed
• Start date: June 8, 2020
• Est. completion date: September 30, 2022

Study information

• Verified date: January 2023
• Source: KK Women's and Children's Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Severe pneumonia is a leading cause of mortality and morbidity in children worldwide. Mortality rates from pediatric severe pneumonia are three times higher in South East Asia compared to the Western hemisphere. The lack of description of epidemiology, current management strategies and outcomes of children with severe pneumonia admitted to pediatric intensive care units (PICUs) in Asia is a barrier to improving pediatric critical care in the region. The lack of a sustainable pediatric critical care network in Asia makes multinational PICU studies challenging. Through the Pediatric Acute & Critical Care Medicine Asian Network (PACCMAN), the investigators aim to estimate the burden of pediatric patients admitted to Asian PACCMAN PICUs due to severe pneumonia that develop pediatric acute respiratory distress syndrome. The investigators will characterize etiologies, identify risk factors associated with morbidity and mortality, and develop prognostic prediction models. The investigators hypothesize that there are non-modifiable (e.g., etiological agents) and modifiable risk factors (e.g., steroid therapy and ventilator strategies) that are associated with poor clinical outcomes. To achieve these aims, the investigators propose a prospective multicenter cohort study over 24 months to recruit 2000 children with severe pneumonia. Pertinent demographic, clinical, microbiological, critical care support and management data will be collected to enable an investigation of the association between risk factors and clinical outcomes in these children. Upon completion of this large observational study, the investigators will have a rich database with detailed information on epidemiology, management strategies and clinical outcomes for severe pneumonia in Asian children.

Description:

The Pediatric Acute & Critical Care Medicine Asian Network (PACCMAN) is the first pediatric critical care network in Asia. Through this network and this study, the investigators aim to provide a comprehensive epidemiological description, clinical management and outcomes of critically ill children with severe pneumonia across multiple sites in Asia. Through PACCMAN, the investigators aim to collect clinical data across at least 10 countries on children admitted to PICUs for severe pneumonia. Detailed data on aetiologies (not limited to vaccine-preventable pneumonia), broad age groups (not limited to a specific age group of children), and specific and supportive therapies in the PICU, will allow the investigators to perform comparative analysis of important non-modifiable and modifiable risk factors associated with mortality and functional outcomes in a large cohort of children with severe pneumonia. This sets the stage for multi-center studies to investigate the effectiveness of intensive care therapies on the outcomes of children with severe pneumonia. The overall aim is to study the epidemiology of severe pneumonia is Asian children and compare the effectiveness of currently employed management strategies (related to invasive mechanical ventilation, adjunct and metabolic support) on clinical outcomes in approximately 2000 children with severe pneumonia admitted to PICUs across at least 10 countries in Asia. The specific aims of this study are as follows: Primary Aim: To (1) estimate the percentage of pediatric patients admitted to PACCMAN PICUs due to severe pneumonia; (2) estimate the percentage of pediatric patients admitted to PICUs for severe pneumonia that develop pediatric acute respiratory distress syndrome (PARDS) prior to PICU discharge or transfer; (3) estimate the overall and PARDS-specific mortality rates for children admitted for severe pneumonia; (4) characterize/classify etiologies of severe pneumonia according to the WHO criteria. Secondary Aim 1: Obtain distributions and estimates of 28-day ventilation free days and 28-day PICU free days; estimate the proportion of patients requiring extracorporeal membrane oxygenation. Secondary Aim 2: Identify risk factors associated with morbidity and mortality rates in children with severe pneumonia in Asia.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 931
• Est. completion date: September 30, 2022
• Est. primary completion date: September 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 1 Day to 18 Years

Eligibility

Inclusion Criteria:

1. Children < 18 years old.

2. Admitted to one of the PICUs in the collaborative network.

3. Evidence of acute infection as defined as reported fever, documented fever or hypothermia, leukocytosis or leucopenia.

4. Evidence of acute respiratory illness as defined as new cough or sputum production, chest pain, dyspnea, tachypnea, abnormal respiratory examination findings or respiratory failure.

5. Radiological evidence of pneumonia within 72 hours before or after admission.

Exclusion Criteria:

1. Children with active do-not-resuscitate (DNR) orders

2. Children that have already been enrolled in this study within the previous 28 days

3. Have an alternative diagnosis of a respiratory disorder

Related Conditions & MeSH terms

• Pneumonia

Intervention

Other:
• Data collection
Demographic, clinical, microbiological, critical care support and management data will be collected.

Locations

Country	Name	City	State
Singapore	KK Women and Children Hospital	Singapore

Sponsors (3)

Lead Sponsor	Collaborator
KK Women's and Children's Hospital	Singapore Clinical Research Institute, Singhealth Foundation

Country where clinical trial is conducted

Singapore, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of pediatric patients admitted to PACCMAN PICUs due to severe pneumonia	Estimate the percentage of pediatric patients admitted to PACCMAN PICUs due to severe pneumonia	Throughout the study, over 24 months
Primary	Percentage of pediatric patients admitted to PICUs for severe pneumonia that develop pediatric acute respiratory distress syndrome (PARDS) prior to PICU discharge or transfer	Estimate the percentage of pediatric patients admitted to PICUs for severe pneumonia that develop pediatric acute respiratory distress syndrome (PARDS) prior to PICU discharge or transfer	Throughout the study, over 24 months
Primary	Overall and PARDS-specific mortality rates for children admitted for severe pneumonia	Estimate the overall and PARDS-specific mortality rates for children admitted for severe pneumonia	Throughout the study, over 24 months
Primary	Characterize/classify etiologies of severe pneumonia in children	Incidence of viral, bacterial and fungal severe pneumonia in children based on microbiological investigations performed as per standard of care.	Throughout study period, over 24 months
Secondary	Obtain distributions and estimates of 28-day ventilation free days in patients with severe pneumonia.	Obtain distributions and estimates of 28-day ventilation free days.	Up to 28 days of mechanical ventilation
Secondary	Obtain distributions and estimates of 28-day PICU free days.	Obtain distributions and estimates of 28-day PICU free days.	Up to 28 days of PICU stay
Secondary	Estimate the proportion of patients severe pneumonia requiring extracorporeal membrane oxygenation.	Total number of patients and proportion of patients with severe pneumonia requiring extracorporeal membrane oxygenation.	Throughout the study period, 24 months